After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved ... The drug – generated using Seaport's Glyph technology – recently started a phase ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

US clinical-stage biotherapeutics company, Seaport Therapeutics’ investigational allopregnanolone prodrug, SPT-300, has been well tolerated in a Phase I trial. The company has published data ...

Seaport Therapeutics (“Seaport” or the “Company ... held back by limitations that are overcome with its proprietary Glyph ™ technology platform. All the therapeutic candidates in ...

“Seaport is advancing novel therapeutics that have proven clinical efficacy but had previously been held back by an issue we can now address with our Glyph platform. This financing enables the ...

The team behind Karuna Therapeutics, the Boston biotech that was bought by drug giant Bristol Myers Squibb in a $14 billion deal in December, launched another company on Tuesday called Seaport ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team ...